# 2025年12月27日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 以患者为中心的肺癌筛查强化：MyLungHealth 随机临床试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41452617)
**期刊：** JAMA oncology
**PMID：** 41452617
**DOI：** 10.1001/jamaoncol.2025.5672

### 第一部分 原文与翻译

**英文原标题：** Enhancement of Patient-Centered Lung Cancer Screening: The MyLungHealth Randomized Clinical Trial.

> **英文摘要：**
> IMPORTANCE: Lung cancer screening (LCS) with low-dose computed tomography (CT) remains underused in the US, partly because of incomplete smoking history documentation in electronic health records (EHRs) and limited time for shared decision-making in primary care.
> 
> OBJECTIVE: To determine whether a patient-facing, EHR-integrated tool combined with clinician-facing clinical decision support improves the identification of LCS-eligible patients and the ordering of low-dose CT compared with clinician-facing tools alone.
> 
> DESIGN, SETTING, AND PARTICIPANTS: This pragmatic, unstratified, randomized clinical trial with parallel groups was conducted from March 29, 2024, to March 28, 2025, at primary care clinics at University of Utah Health and New York University Langone Health. Adults aged 50 to 79 years with a documented smoking history, an active patient portal account, and a primary care visit in the preceding year were included. Study 1 enrolled patients with uncertain LCS eligibility (10 to 19 pack-years, unknown pack-years, or missing quit date); study 2 enrolled patients with documented eligibility (20 or more pack-years and currently smoking or quit smoking within 15 years).
> 
> INTERVENTIONS: The control included the clinician-facing Decision Precision+ tool (preventive care reminders and a shared decision-making tool). The intervention included the Decision Precision+ tool as well as the MyLungHealth tool, which collected detailed smoking history (study 1) and delivered personalized education and risk/benefit information (studies 1 and 2) via the patient portal in English and Spanish.
> 
> MAIN OUTCOMES AND MEASURES: The primary outcomes were the proportion of patients newly identified as eligible for LCS (study 1) and low-dose CT ordering rates (study 2) over 12 months. Analyses used intention-to-treat mixed-effects logistic regression.
> 
> RESULTS: There were 31 303 randomized participants, including 26 729 in study 1 (13 144 [49.2%] female; 13 580 [50.8%] male; median [IQR] age, 62 [55-69] years) and 4574 in study 2 (2230 [48.8%] female; 2344 [51.2%] male; median [IQR] age, 63 [56-69] years). In study 1, the MyLungHealth tool increased new LCS eligibility identification (635 of 13 412 [4.7%] vs 308 of 13 317 [2.3%]; adjusted odds ratio, 2.19; 95% CI, 1.99-2.42; P < .001). In study 2, low-dose CT ordering was higher in the intervention arm (474 of 2312 [20.5%] vs 434 of 2262 [19.2%]; adjusted odds ratio, 1.16; 95% CI, 1.04-1.30; P = .008).
> 
> CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, integrating a patient-centered tool into primary care EHR workflows increased the identification of patients eligible for LCS and the ordering of low-dose CTs. The relative increases in these primary outcomes were substantial, but absolute increases were more modest. Research on more intensive interventions is warranted to evaluate their ability to further improve LCS screening.
> 
> TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06338592.

> **中文摘要：**
> 【重要性】：在美国，低剂量计算机断层扫描（CT）的肺癌筛查（LCS）仍然使用不足，部分原因是电子健康记录（EHR）中吸烟史记录不完整，以及初级保健中用于共同决策的时间有限。
> 
> 【目的】：评估与单纯面向临床医生的决策支持工具相比，一个面向患者、整合于EHR系统的工具结合临床医生决策支持，是否能改善LCS适用患者的识别及低剂量CT的开单率。
> 
> 【设计、场所与参与者】：这项务实性、未分层、平行组随机临床试验于2024年3月29日至2025年3月28日期间，在犹他大学健康系统与纽约大学朗格尼健康系统的初级保健诊所开展。纳入对象为50至79岁、有吸烟史记录、拥有有效的患者门户账户，并在前一年至少有一次初级保健就诊的成人。研究1纳入LCS资格不确定者（吸烟10–19包年、吸烟量未知或戒烟日期缺失）；研究2纳入具有明确资格者（吸烟≥20包年且目前吸烟或戒烟未满15年）。
> 
> 【干预措施】：对照组使用临床医生端Decision Precision+工具（包括预防性健康提醒及共同决策支持工具）。干预组在此基础上增加MyLungHealth工具，该工具通过患者门户（支持英语和西班牙语）采集详细吸烟史（研究1）并提供个性化教育及风险/收益信息（研究1和研究2）。
> 
> 【主要结局与测量指标】：主要结局为在12个月内新识别出的LCS适格患者比例（研究1）及低剂量CT开单率（研究2）。分析采用意向性治疗的混合效应逻辑回归。
> 
> 【结果】：共随机分配31,303名参与者，其中研究1有26,729人（女性13,144人［49.2%］，男性13,580人［50.8%］；中位［四分位数范围］年龄62［55–69］岁），研究2有4,574人（女性2,230人［48.8%］，男性2,344人［51.2%］；中位年龄63［56–69］岁）。研究1中，MyLungHealth工具提高了新识别的LCS适格患者比例（635/13,412［4.7%］vs 308/13,317［2.3%］；校正比值比2.19；95% CI：1.99–2.42；P<.001）。研究2中，干预组低剂量CT开单率更高（474/2,312［20.5%］vs 434/2,262［19.2%］；校正比值比1.16；95% CI：1.04–1.30；P=.008）。
> 
> 【结论与意义】：该随机临床试验证实，将以患者为中心的工具整合至初级保健EHR工作流程，可增加LCS适格患者的识别与低剂量CT开单。尽管相对提升显著，绝对增幅仍较为有限。未来需研究更强化的干预措施，以评估其进一步改善LCS筛查的潜力。
> 
> 【试验注册】：ClinicalTrials.gov编号：NCT06338592。

### 第二部分 AI 大师评价

该研究通过随机对照设计验证了在初级保健系统中整合患者端与医生端双向互动的数字工具对肺癌筛查率的影响。MyLungHealth平台有效改善了患者筛查资格识别及低剂量CT开单比例，体现出以患者为中心的数字策略在公共卫生干预中的可行性与价值。其方法务实、样本量大，但提升幅度有限，提示未来仍需探索更深度行为干预或多层系统整合的方案，以进一步提高筛查落实率。

---

## 2. 接受全身治疗的癌症患者的基线疲劳与严重毒性反应之间的关系

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41452615)
**期刊：** JAMA oncology
**PMID：** 41452615
**DOI：** 10.1001/jamaoncol.2025.5549

### 第一部分 原文与翻译

**英文原标题：** Baseline Fatigue and Severe Toxic Effects in Patients With Cancer Receiving Systemic Therapy.

> **英文摘要：**
> IMPORTANCE: Fatigue is a common symptom reported by patients with cancer, yet its role as a predictor of treatment-related toxic effects has not been well characterized. Understanding whether fatigue measured at treatment initiation may be associated with subsequent toxic effects could help guide individualized treatment planning and symptom monitoring.
> 
> OBJECTIVE: To evaluate the association between baseline patient-reported fatigue and the risk of adverse events (AEs) in cancer treatment trials.
> 
> DESIGN, SETTING, AND PARTICIPANTS: This cohort study and pooled analysis assessed baseline fatigue data from 17 SWOG phase 2 and 3 trials conducted from 1990 to 2022. Patients were enrolled across multiple cancer types and treatment settings. Data analysis was performed from March 1, 2023, to October 17, 2025.
> 
> EXPOSURES: Baseline fatigue, classified on a 5-point Likert scale, analyzed as binary thresholds (eg, <some vs ≥some fatigue) and across fatigue severity levels.
> 
> MAIN OUTCOMES AND MEASURES: Adverse events were classified using the Common Terminology Criteria for Adverse Events (CTCAE), with multiple versions mapped to version 4. Symptomatic AEs followed the Patient-Reported Outcomes-CTCAE framework; laboratory-based or measurable toxic effects were considered objective (hematologic vs nonhematologic). Primary outcomes were grade 3 or higher (severe), grade 4 or higher (life-threatening), and grade 5 (fatal) AEs. Odds ratios (ORs) were estimated using generalized estimating equations. To account for confounding, the analysis was clustered by trial and adjusted for age, sex, race, and obesity.
> 
> RESULTS: Among 7086 patients (mean [SD] age, 62.1 [15.2] years; 2107 females [29.7%] and 4979 males [70.3%]) with prostate, lung, colorectal, lymphoma, breast, melanoma, ovarian, or pancreatic cancer, 103 738 AEs were reported. At baseline, 2771 participants (39.1%) reported some or more fatigue. Proportions with maximum AEs rated grade 3 or higher, grade 4 or higher, and grade 5 were 3128 participants (44.1%), 1001 (14.1%), and 62 (0.9%), respectively. Compared with those reporting no or minimal fatigue, patients with some fatigue or more had higher risks of severe or worse toxic effects (odds ratio [OR], 2.09; 95% CI, 1.58-2.78; P < .001), life-threatening or fatal toxic effects (OR, 1.96; 95% CI, 1.36-2.82; P < .001), and fatal toxic effects (OR, 2.35; 95% CI, 1.07-5.19; P = .03). A dose-response pattern was evident: patients reporting quite a lot or very much fatigue had an approximately 5-fold higher risk of fatal toxic effects (OR, 4.99; 95% CI, 1.84-13.51; P = .002). Findings were consistent across symptomatic, hematologic, and nonhematologic AE categories.
> 
> CONCLUSIONS AND RELEVANCE: This cohort study found that baseline patient-reported fatigue was associated with an increased risk of cancer treatment-related toxic effects. Fatigue assessments at treatment initiation may serve as an early clinical marker of risk for toxic effects and may help inform personalized treatment strategies and symptom monitoring.

> **中文摘要：**
> 重要性：疲劳是癌症患者常报告的症状之一，但其作为治疗相关毒性反应预测指标的作用尚未得到充分表征。了解在治疗开始时测量的疲劳是否与后续毒性反应相关，可能有助于指导个体化治疗方案与症状监测。
> 
> 研究目的：评估患者自报基线疲劳与癌症治疗试验中不良事件（AEs）风险之间的关联。
> 
> 研究设计、地点与参与者：本队列研究及汇总分析评估了1990年至2022年期间开展的17项SWOG Ⅱ期和Ⅲ期试验的基线疲劳数据。患者涵盖多种肿瘤类型及治疗情境。数据分析时间为2023年3月1日至2025年10月17日。
> 
> 暴露因素：基线疲劳采用5点李克特量表分级，按二分类阈值（例如 <某程度 vs ≥某程度疲劳）及不同疲劳严重程度进行分析。
> 
> 主要结局与测量指标：不良事件根据《不良事件通用术语标准》（CTCAE）进行分类，多版本映射至第4版。症状性不良事件遵循“患者报告结局-CTCAE”框架；实验室或量化性毒性反应视为客观事件（血液学与非血液学）。主要结局为3级及以上（严重）、4级及以上（危及生命）及5级（致死）不良事件。采用广义估计方程（GEE）估算比值比（OR），按试验聚类，并校正年龄、性别、种族和肥胖等混杂因素。
> 
> 结果：纳入7086名患者（平均[标准差]年龄62.1[15.2]岁；女性2107人[29.7%]，男性4979人[70.3%]），包括前列腺癌、肺癌、结直肠癌、淋巴瘤、乳腺癌、黑色素瘤、卵巢癌及胰腺癌，共报告103,738起不良事件。基线时，2771名参与者（39.1%）报告存在一定程度或以上疲劳。最高不良事件为3级及以上、4级及以上和5级的患者比例分别为3128人（44.1%）、1001人（14.1%）及62人（0.9%）。与无或轻微疲劳者相比，存在一定疲劳或更严重疲劳的患者发生严重或更高等级毒性反应的风险更高（OR=2.09；95%CI，1.58–2.78；P<.001），危及生命或致死毒性反应风险增高（OR=1.96；95%CI，1.36–2.82；P<.001），致死性毒性风险亦显著升高（OR=2.35；95%CI，1.07–5.19；P=0.03）。剂量反应关系明显：报告“相当多”或“非常多”疲劳的患者其致死毒性风险约提高5倍（OR=4.99；95%CI，1.84–13.51；P=0.002）。结果在症状性、血液学及非血液学不良事件类别中表现一致。
> 
> 结论与意义：本队列研究发现，患者自报的基线疲劳与癌症治疗相关毒性反应风险增加相关。治疗开始时的疲劳评估可能成为早期毒性风险的临床标志，有助于制定个体化治疗策略并优化症状监测。

### 第二部分 AI 大师评价

本研究利用17项SWOG临床试验的大规模汇总数据，系统评估了癌症患者在治疗前自报疲劳与后续严重毒性反应之间的关系。结果显示，基线疲劳显著关联于高等级不良事件风险，且存在明确剂量-反应趋势。研究方法学上采用统一CTCAE标准和多层校正分析，增强了结论的可靠性。此研究创新性地提出了“自报疲劳”作为早期毒性预测指标的潜在价值，但因其观察性性质，仍需进一步验证其因果关系及实际临床应用策略。

---

## 3. 倾向评分匹配分析中的疑虑——答复

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41452614)
**期刊：** JAMA oncology
**PMID：** 41452614
**DOI：** 10.1001/jamaoncol.2025.5561

### 第一部分 原文与翻译

**英文原标题：** Concerns in the Propensity Score-Matched Analysis-Reply.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该篇文章为对倾向评分匹配分析方法所引发问题的学术回应，重点在于进一步澄清先前研究中统计方法的适用性与解释界限。虽然缺乏摘要细节，但从标题可推测其目的在于回应学界质疑，强调方法学的严谨性与透明度。总体而言，此回复有助于促进临床研究中因果推断方法的规范化与科学讨论的深入。

---

## 4. 在包含PD-1或PD-L1药物的国家癌症研究所临床试验中观察到的免疫检查点抑制剂相关糖尿病

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41452607)
**期刊：** JAMA oncology
**PMID：** 41452607
**DOI：** 10.1001/jamaoncol.2025.5594

### 第一部分 原文与翻译

**英文原标题：** Immune Checkpoint Inhibitor-Induced Diabetes Across National Cancer Institute Trials That Included PD-1 or PD-L1 Agents.

> **英文摘要：**
> IMPORTANCE: Immune-related adverse events (IRAEs) limit the use of cancer immunotherapy. Understanding the risk of severe IRAEs may help improve the use of cancer immunotherapy.
> 
> OBJECTIVE: To review and assess hyperglycemic events across thousands of patients to characterize immune checkpoint inhibitor (ICI)-induced diabetes (ICI-D) using a large-scale trial conglomerate.
> 
> DESIGN, SETTING, AND PARTICIPANTS: Adverse event (AE) reports related to diabetes, hyperglycemia, and acidosis were retrieved from the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP) database. Trial data from June 2015 to December 2022 were analyzed. Clinical information was manually retrieved. Overall counts of patients on each trial were retrieved from central NCI data. NCI CTEP trials are hosted in both academic and community medical centers. This analysis includes patients across 158 trials who were treated with varying regimens that included programmed cell death 1 protein (PD-1) or programmed cell death 1 ligand 1 (PD-L1) inhibitors through an NCI CTEP trial for their cancer from June 2015 to December 2022. Data clarifications were requested and then data were analyzed from January 2023 to June 1, 2025.
> 
> MAIN OUTCOMES AND MEASURES: Clinical characteristics differentiating ICI-D from other causes of hyperglycemia were enumerated. Cumulative incidence rates of ICI-D were calculated using trial-level data. Logistic regression was used to calculate the odds of developing ICI-D.
> 
> RESULTS: In 13 966 patients across 158 trials, the overall cumulative incidence of ICI-D was low (0.52 per 100 treated patients), but incidence varied by treatment type and was lower if patients were exposed to concurrent chemotherapy (0.65% without chemotherapy vs 0.26% with chemotherapy; odds ratio [OR], 0.38; 95% CI, 0.21-0.71; P = .002) and higher if patients were exposed to combined immunotherapy (0.94% with combination immunotherapy vs 0.37% with PD-1/PD-L1 inhibitor monotherapy; OR, 2.68; 95% CI, 1.69-4.24). Despite these low rates, the health care burden of ICI-D was high, with 90% requiring hospitalization at diagnosis and 43% requiring intensive care. The degree of hyperglycemia can be used to differentiate different etiologies of hyperglycemia, with higher glucose levels being more likely to be due to ICI-D.
> 
> CONCLUSIONS AND RELEVANCE: Results of this study suggest that ICI-D is a rare but morbid condition that varies based on the combination of ICIs with other agents.

> **中文摘要：**
> 研究重要性：免疫相关不良事件（IRAEs）限制了癌症免疫治疗的使用。理解严重IRAEs的风险有助于改进免疫治疗的应用。
> 
> 研究目的：通过回顾并评估数千名患者的高血糖事件，利用大规模临床试验数据综合体来表征免疫检查点抑制剂（ICI）诱导的糖尿病（ICI-D）。
> 
> 研究设计、设定与参与者：从美国国家癌症研究所（NCI）癌症治疗评估项目（CTEP）数据库检索与糖尿病、高血糖和酸中毒相关的不良事件（AE）报告。分析2015年6月至2022年12月的试验数据，临床信息通过人工方式提取。每个试验的总体入组人数取自NCI中央数据。NCI CTEP试验既在学术医疗中心也在社区医疗机构进行。本分析包括158项试验中接受含有程序性细胞死亡蛋白1（PD-1）或其配体（PD-L1）抑制剂治疗的癌症患者，时间跨度为2015年6月至2022年12月。数据澄清请求完成后，于2023年1月至2025年6月1日分析数据。
> 
> 主要结局与测量指标：列举用于区分ICI-D与其他高血糖原因的临床特征。利用试验层面的数据计算ICI-D的累积发病率。通过逻辑回归计算发生ICI-D的比值比。
> 
> 研究结果：在158项试验共13,966名患者中，ICI-D的总体累积发病率较低（每100名治疗患者0.52例），但不同治疗类型之间存在差异。暴露于同期化疗的患者发病率较低（未接受化疗0.65%，接受化疗0.26%；比值比[OR]，0.38；95%置信区间[CI]，0.21–0.71；P = .002），而接受联合免疫治疗的患者发病率较高（联合免疫治疗0.94%，单药PD-1/PD-L1抑制剂0.37%；OR，2.68；95% CI，1.69–4.24）。尽管总体发病率低，但ICI-D的医疗负担较重，90%的患者在诊断时需要住院，且43%需要重症监护。高血糖程度可用于区分不同病因的高血糖，其中更高的血糖水平更可能由ICI-D引起。
> 
> 研究结论与意义：研究结果表明，ICI-D是一种罕见但病程严重的疾病，其发生与免疫检查点抑制剂联合其他药物的治疗方案相关。

### 第二部分 AI 大师评价

本研究系统分析了美国国家癌症研究所CTEP数据库中PD-1/PD-L1相关临床试验的高血糖事件，揭示了免疫检查点抑制剂诱导糖尿病虽发病率低但病情严重。研究通过合理的逻辑回归分析量化了不同治疗组合对风险的影响，发现联合免疫治疗显著提高ICI-D风险，而化疗合用可降低风险。其创新在于利用国家级数据库进行大规模整合分析，为免疫治疗安全性评估提供了循证依据。局限性在于事件的人工确认依赖及临床资料缺失，后续研究需进一步验证机制与预防策略。

---

## 5. 肿瘤药物收入与价格谈判

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41452598)
**期刊：** JAMA oncology
**PMID：** 41452598
**DOI：** 10.1001/jamaoncol.2025.5385

### 第一部分 原文与翻译

**英文原标题：** Oncology Drug Revenue and Price Negotiation.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要可用。

### 第二部分 AI 大师评价

该研究关注肿瘤药物市场收入与价格谈判机制之间的关系，探讨药品定价政策对肿瘤学领域经济结构及可及性的潜在影响。尽管尚未公布摘要，标题提示其可能评估当前价格谈判机制对药物收入分布、支付体系或创新激励的影响。该主题具有重要政策启发意义，或为未来药品成本控制与医疗公平性提供实证基础。但由于缺乏摘要，目前研究设计与具体结果尚不明确。

---

## 6. 用于多尺度生物系统可视化与临床转化的光声显微成像

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41449765)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41449765
**DOI：** 10.1002/advs.202521173

### 第一部分 原文与翻译

**英文原标题：** Photoacoustic Microscopy for Multiscale Biological System Visualization and Clinical Translation.

> **英文摘要：**
> Photoacoustic microscopy (PAM) has emerged as a versatile modality in biomedical research, notable for its noninvasively, high spatial resolution, and superior optical contrast. Compared with pure optical imaging techniques, PAM leverages weakly scattered ultrasonic signals for image formation, thereby achieving high-resolution visualization of deep tissues. This review provides a comprehensive synthesis of recent advancements in PAM, encompassing technological innovations, organ-specific applications, and emerging pathways toward clinical translation. This discussion starts by exploring the fundamental physical principles of PAM and elaborates on the enhanced performance achieved through significant advancements in high-speed scanners, array transducers, artificial intelligence-enhanced algorithms, and molecular agents. Pioneering applications in single‑cell analysis, hepatic microcirculation characterization, renal clearance monitoring, tumor metastasis detection, and neuroscientific discovery are surveyed to demonstrate PAM's ability. Prospective clinical uses, including intraoperative guidance and point‑of‑care diagnostics, are considered alongside persistent limitations, notably limited penetration depth and multispectral imaging speed. Future advancements are expected to hinge on multimodal integration, deeper integration of artificial intelligence, and the development of standardized protocols to accelerate clinical implementation. Ultimately, this review offers a forward-looking perspective aimed at accelerating the translation of PAM from a laboratory tool to a clinical mainstay in the era of precision medicine.

> **中文摘要：**
> 光声显微成像（PAM）已成为生物医学研究中的一种多功能成像方式，以其非侵入性、高空间分辨率和优越的光学对比度而著称。与纯光学成像技术相比，PAM 利用弱散射的超声信号进行图像重建，从而实现深层组织的高分辨率可视化。本综述系统总结了 PAM 的最新进展，包括技术创新、器官特异性应用以及面向临床转化的新兴路径。讨论首先探讨了 PAM 的基本物理原理，并详细阐述了通过高速扫描仪、阵列换能器、人工智能增强算法及分子探针等重大技术进步所带来的性能提升。综述还调查了其在单细胞分析、肝脏微循环表征、肾清除监测、肿瘤转移检测及神经科学研究等领域的开创性应用，以展示 PAM 的能力。针对潜在的临床用途（如术中导航及即时诊断），文章也讨论了仍然存在的限制，主要包括有限的穿透深度和多光谱成像速度不足。未来的发展预计将依赖于多模态整合、更深层的人工智能结合，以及标准化操作规程的建立，以加速其临床应用。最终，本综述从前瞻性角度提供了见解，旨在推动 PAM 从实验室工具向精准医学时代的临床核心技术转化。

### 第二部分 AI 大师评价

该文系统综述了光声显微成像在多尺度生物系统可视化及临床转化中的最新进展。作者不仅阐释了其物理原理，还重点分析了在硬件、算法和分子探针方面的关键创新。文中涵盖了单细胞到器官层面的多种应用场景，并评估了潜在的临床前景与仍存的技术瓶颈。该综述的创新之处在于全面结合人工智能与多模态成像的发展趋势，为未来的临床标准化与实际转化提供了战略性方向。

---

## 7. 基于参考序列的染色体逐条大规模 de novo 组装方法：利用低覆盖度高保真长读长与 HiFiCCL 框架

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41449706)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41449706
**DOI：** 10.1002/advs.202515308

### 第一部分 原文与翻译

**英文原标题：** Reference-Guided Chromosome-by-Chromosome de novo Assembly at Scale Using Low-Coverage High-Fidelity Long-Reads with HiFiCCL.

> **英文摘要：**
> Population genomics using short-read resequencing captures single-nucleotide polymorphisms and small insertions and deletions but struggles with structural variants, leading to a loss of heritability in genome-wide association studies. In recent years, long-read sequencing has improved pangenome construction for diverse eukaryotic species, including humans, crops, and other organisms of ecological and economic importance, addressing this issue to some extent. Sufficient-coverage high-fidelity data for population genomics is often prohibitively expensive, limiting its use in large-scale populations and broader eukaryotic species and creating an urgent need for robust low-coverage assemblies. However, current assemblers underperform in such conditions. To address this, HiFiCCL is proposed, the first assembly framework specifically designed for low-coverage high-fidelity reads, using a reference-guided, chromosome-by-chromosome assembly approach. This study demonstrates that HiFiCCL improves low-coverage assembly performance of existing assemblers and outperforms the state-of-the-art assemblers on human and plant datasets. Tested on 45 human datasets (∼5× coverage), HiFiCCL combined with hifiasm reduces the length of misassembled contigs relative to hifiasm by an average of 21.19% and up to 38.58%. These improved assemblies excel in detecting large germline structural variants, minimize inter-chromosome mis-scaffolding, and improve the detection of specific germline and tumor somatic structural variants based on the pangenome graph.

> **中文摘要：**
> 利用短读长重测序的群体基因组学能够捕获单核苷酸多态性及小的插入和缺失，但在检测结构变异方面存在困难，从而导致全基因组关联研究中可遗传性损失。近年来，长读长测序在包括人类、作物以及其他具有生态或经济重要性的真核物种中改进了泛基因组构建，在一定程度上解决了这一问题。然而，用于群体基因组学的足够覆盖度高保真数据往往成本高昂，限制了其在大规模群体和更广泛的真核物种中的应用，因此迫切需要稳健的低覆盖组装方法。然而，目前的组装程序在此条件下表现不佳。为此，本文提出了 HiFiCCL，这是首个专为低覆盖度高保真读长设计的组装框架，采用基于参考序列的、按染色体逐条组装的方法。本研究显示，HiFiCCL 能够提升现有组装程序在低覆盖条件下的表现，并在人体和植物数据集中优于当前最先进的组装工具。在 45 个人类数据集（约 5× 覆盖度）上测试时，HiFiCCL 结合 hifiasm 相比单独使用 hifiasm，可使误组装的 contig 长度平均减少 21.19%，最高达 38.58%。这些改进后的组装在检测大型生殖系结构变异方面表现优异，显著减少了染色体间的错误拼接，并在基于泛基因组图的特定生殖系及肿瘤体细胞结构变异检测中实现了改进。

### 第二部分 AI 大师评价

该研究旨在解决低覆盖度高保真读长在群体基因组组装中的性能瓶颈。研究者开发了 HiFiCCL 框架，通过结合参考序列的染色体逐条组装策略，显著提升了低覆盖组装的准确性与完整性。结果显示，HiFiCCL 在人类和植物数据集中均优于现有主流组装器，显著减少误组装并提升结构变异检测能力。该方法的创新性在于高效融合低覆盖长读长数据与参考指导策略，为大规模群体泛基因组学提供了可行方案。然而，其性能在极端低覆盖度或高复杂结构基因组中的稳定性仍需进一步验证。

---

## 8. 揭示促红细胞生成素变体EV-3作为人胶质母细胞瘤的新型驱动因子和免疫治疗靶点

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41449467)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41449467
**DOI：** 10.1186/s13046-025-03620-3

### 第一部分 原文与翻译

**英文原标题：** Revealing erythropoietin variant EV-3 as novel driving force and immunotherapeutic target in human glioblastoma.

> **英文摘要：**
> BACKGROUND: Glioblastoma is the most aggressive primary brain tumor, and, despite intensive studies, remains one of the most fatal malignancy in adult humans. Among multiple onco-promoters produced by glioblastoma cells, erythropoietin was found. However, the presence/function of Epo alternatively spliced variants in cancer remains unexplored. Here, we investigated the expression and role of Epo-variants in glioblastoma, and the therapeutic potential of their targeting through a novel monoclonal antibody (mAb).
> 
> METHODS: Transcripts and protein levels of Epo-variants in a cohort of human brain tumors were evaluated by RT-PCR, ELISA, and immunohistochemistry. Monoclonal antibodies targeting Epo-Vs were prepared and functionally selected by assaying proliferation, migration, stemness, and angiogenesis in glioblastoma patient-derived cells. Antibody affinity for Epo/Epo-variant was determined by SPR. In vivo toxicity and therapeutic efficacy of the lead antibody were evaluated in GBM mouse models.
> 
> RESULTS: We found a significant overexpression of Epo-variant transcripts in tissues and cells from GBM patients. After functional selection of newly-produced antibodies, we identified AND-C4 as the lead one for its potent anti-tumoral properties, absence of anti-erythropoietic effects and of toxicity on human brain cells. AND-C4 exhibited high affinity for the Epo-variant EV-3. We demonstrated that EV-3 was efficiently produced and secreted by glioblastoma cells, particularly by stem cells. EV-3 exerted tumorigenic, angiogenic and immunomodulatory properties, and AND-C4 was effective in antagonizing all these actions. In vivo studies in rodent glioblastoma models revealed that AND-C4 selectively bound to tumor tissue and exhibited significant efficacy on tumor growth and animal survival.
> 
> CONCLUSION: This study represents the first evidence on the presence, origin and pro-tumoral activity of EV-3 in human glioblastoma. Moreover, in vitro and in vivo results revealed AND-C4 as novel and promising anti-glioblastoma immunotherapeutic.

> **中文摘要：**
> 背景：胶质母细胞瘤是最具侵袭性的原发性脑肿瘤，尽管已进行了大量研究，但它仍是成人中最致命的恶性肿瘤之一。在胶质母细胞瘤细胞产生的多种致癌促进因子中，发现了促红细胞生成素（Epo）。然而，Epo可变剪接变体在癌症中的存在及功能尚未得到探索。本研究旨在探讨Epo变体在胶质母细胞瘤中的表达及作用，并评估针对这些变体的新型单克隆抗体（mAb）的治疗潜力。
> 
> 方法：通过RT-PCR、ELISA和免疫组织化学分析评估了人脑肿瘤队列中Epo变体的转录本和蛋白水平。制备靶向Epo变体的单克隆抗体，并通过检测来源于胶质母细胞瘤患者细胞的增殖、迁移、干性及血管生成功能筛选抗体活性。通过SPR测定抗体对Epo及其变体的结合亲和力。在胶质母细胞瘤小鼠模型中评估领先抗体的体内毒性和治疗效果。
> 
> 结果：我们发现来自胶质母细胞瘤患者组织和细胞中的Epo变体转录本显著过表达。通过功能筛选，新生成的抗体中确定了AND-C4为领先候选，因其具有强大的抗肿瘤特性、无抗促红细胞生成作用及对人脑细胞的无毒性。AND-C4对Epo变体EV-3表现出高度亲和力。研究表明，胶质母细胞瘤细胞，尤其是干细胞，可高效产生并分泌EV-3。EV-3具有促肿瘤、促血管生成及免疫调节特性，而AND-C4可有效拮抗这些作用。啮齿类动物胶质母细胞瘤模型的体内研究显示，AND-C4可选择性结合肿瘤组织，并显著抑制肿瘤生长及改善动物生存。
> 
> 结论：本研究首次证实了EV-3在人体胶质母细胞瘤中的存在、来源及促肿瘤活性。此外，体内外研究结果表明，AND-C4是一种新型且具有潜力的抗胶质母细胞瘤免疫治疗药物。

### 第二部分 AI 大师评价

本研究系统揭示了Epo可变剪接变体EV-3在胶质母细胞瘤中的表达特征及其促肿瘤作用，并通过新开发的单克隆抗体AND-C4实现了针对性阻断。研究方法涵盖分子、细胞及动物模型验证，证据链完整，结果证明EV-3不仅驱动肿瘤进展，还具免疫调节功能。AND-C4显示出选择性、高亲和力和良好安全性，突显出其潜力作为新型免疫治疗药物。研究创新性强，但后续仍需临床验证以评估其实际疗效与安全性。

---

## 9. 抑制素βA通过促进巨噬细胞M2型极化和抑制线粒体依赖性铁死亡驱动结直肠癌进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41449244)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41449244
**DOI：** 10.1038/s41392-025-02518-y

### 第一部分 原文与翻译

**英文原标题：** Inhibin beta A drives colorectal cancer progression through macrophage M2 polarization and mitochondria-dependent ferroptosis suppression.

> **英文摘要：**
> Colorectal cancer (CRC) is a prevalent malignant tumor, and its pathogenesis has not yet been fully elucidated. The tumor microenvironment (TME) and ferroptosis in cancer cells are key drivers of tumor progression and metastasis. This research revealed that elevated INHBA expression in CRC tissues correlates with unfavorable clinical outcomes. In vitro and in vivo studies demonstrated that elevated INHBA enhances CRC cellular growth, migration, and invasion, whereas INHBA knockdown inhibits these malignant biological behaviors. Further investigation revealed that INHBA drives malignancy by reprogramming tumor-associated macrophages (TAMs) toward the M2 phenotype in the TME and by inhibiting mitochondrial-dependent ferroptosis in CRC cells. Mechanistically, INHBA upregulates SLC25A10 to activate the succinate/SUCNR1 axis, thus facilitating M2-like TAM polarization. It also activates the mitochondrial glutathione (mtGSH)/glutathione peroxidase 4 (GPX4) pathway to suppress mitochondria-dependent ferroptosis in CRC cells. Additionally, INHBA acts as a scaffold protein to inhibit TRIM21-mediated ubiquitination and degradation of SLC25A10, thereby stabilizing the SLC25A10 protein. In summary, INHBA drives tumor progression by remodeling the immune microenvironment and antagonizing ferroptosis in CRC cells, providing a theoretical basis for developing INHBA-targeted inhibitors or combined immunoferroptosis therapeutic strategies. Mechanisms of INHBA in colorectal cancer In colorectal cancer, INHBA is upregulated. Acting as a scaffold protein, INHBA inhibits the K48-linked ubiquitination and degradation of the mitochondrial protein SLC25A10, mediated by the E3 ubiquitin ligase TRIM21. This inhibition leads to the upregulation of SLC25A10 expression. The upregulated SLC25A10 facilitates the transport of succinate from the mitochondrial matrix to the cytoplasm and further secretes it outside the tumor cells. The secreted succinate binds to SUCNR1 on macrophages, activating the succinate/SUCNR1 axis, which in turn promotes the M2 polarization of tumor-associated macrophages (TAMs). Meanwhile, SLC25A10, as one of the key mitochondrial glutathione (mtGSH) transporters embedded in the mitochondrial inner membrane, promotes the transport of glutathione (GSH) synthesized in the cytoplasm into the mitochondria. This process activates the mitochondrial GSH-GPX4 axis, thereby inhibiting mitochondrial ferroptosis. Through these two mechanisms, INHBA ultimately promotes the malignant progression of colorectal cancer.

> **中文摘要：**
> 结直肠癌（CRC）是一种常见的恶性肿瘤，其发病机制尚未完全阐明。肿瘤微环境（TME）和癌细胞中的铁死亡是肿瘤进展与转移的重要驱动因素。本研究发现，CRC组织中INHBA的高表达与不良临床结局相关。体内外实验表明，INHBA的高表达可促进CRC细胞的生长、迁移和侵袭，而敲低INHBA可抑制这些恶性生物学行为。进一步研究显示，INHBA通过在TME中将肿瘤相关巨噬细胞（TAMs）重编程为M2表型，并抑制CRC细胞的线粒体依赖性铁死亡，从而驱动肿瘤恶性进展。在机制上，INHBA上调SLC25A10的表达，激活琥珀酸/SUCNR1轴，从而促进TAMs的M2样极化。同时，INHBA激活线粒体谷胱甘肽（mtGSH）/谷胱甘肽过氧化物酶4（GPX4）通路，抑制CRC细胞的线粒体依赖性铁死亡。此外，INHBA作为支架蛋白，可抑制E3泛素连接酶TRIM21介导的SLC25A10的泛素化和降解，从而稳定SLC25A10蛋白。综上所述，INHBA通过重塑免疫微环境并拮抗CRC细胞的铁死亡促进肿瘤进展，为开发靶向INHBA的抑制剂或联合免疫-铁死亡治疗策略提供了理论依据。在结直肠癌中，INHBA上调。作为支架蛋白，INHBA抑制E3泛素连接酶TRIM21介导的线粒体蛋白SLC25A10的K48连接型泛素化与降解，从而上调SLC25A10的表达。上调后的SLC25A10促进琥珀酸从线粒体基质转运至胞质并进一步分泌到肿瘤细胞外。分泌的琥珀酸与巨噬细胞上的SUCNR1结合，激活琥珀酸/SUCNR1轴，从而诱导肿瘤相关巨噬细胞的M2型极化。同时，作为嵌入线粒体内膜的关键线粒体谷胱甘肽（mtGSH）转运蛋白之一，SLC25A10促进细胞质中合成的谷胱甘肽（GSH）进入线粒体，从而激活线粒体GSH-GPX4轴，抑制线粒体铁死亡。通过这两种机制，INHBA最终促进结直肠癌的恶性进展。

### 第二部分 AI 大师评价

该研究系统揭示了INHBA通过调控肿瘤免疫微环境重塑及线粒体铁死亡抑制促进结直肠癌进展的机制。作者综合运用体内外功能实验、分子互作验证以及代谢信号通路分析，确立了INHBA–SLC25A10–SUCNR1轴与mtGSH–GPX4轴的双重作用模式。该发现为INHBA作为创新性免疫-铁死亡联合治疗靶点提供了坚实的理论支持。研究创新性突出，但其临床转化价值及特异性靶向策略仍需进一步验证。

---

## 10. 乳腺癌转移灶及正常组织尸检样本中抗体-药物偶联物靶点的表达分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41449182)
**期刊：** Nature communications
**PMID：** 41449182
**DOI：** 10.1038/s41467-025-67840-z

### 第一部分 原文与翻译

**英文原标题：** Expression of antibody-drug conjugate targets in post-mortem samples of breast cancer metastases and normal tissue.

> **英文摘要：**
> While many Antibody Drug Conjugates (ADCs) are investigated in solid tumors, their target expression and heterogeneity is poorly documented in metastatic breast cancer. Here, we perform RNA sequencing to investigate expression of 72 ADC targets in 909 samples from 30 female patients from our post-mortem tissue donation program UPTIDER (NCT04531696). We report that the highest median expression in metastases is seen for FN1, MUC1, LAMP1, HER3 and SLC39A6. TROP2 and HER2 have the 9 and 27 highest expression. We observe reduced expression in metastases as compared to primary untreated tumors for 15 targets but observe only limited differences in expression between metastases of different subtypes. We show that TROP2, VTCN1, NECTIN4, HER2 and HER3 are interesting targets as they have higher mRNA expression in tumor as compared to normal tissues. This is confirmed at the protein level by explorative immunohistochemistry. Correlations between targets can help guide design of bispecific ADCs. Taken together, the results of this study can help inform the design and prioritization of drugs for the treatment of patients with metastatic breast cancer.

> **中文摘要：**
> 尽管许多抗体-药物偶联物（ADCs）已在实体瘤中进行研究，但其在转移性乳腺癌中的靶点表达及异质性仍缺乏系统记录。本研究通过RNA测序，分析来自尸检组织捐献项目UPTIDER（NCT04531696）的30名女性患者的909份样本中72个ADC靶点的表达情况。结果显示，在转移灶中，FN1、MUC1、LAMP1、HER3和SLC39A6的中位表达水平最高；TROP2和HER2分别位列第9和第27位。与未经治疗的原发肿瘤相比，有15个靶点在转移灶中表达下调，但不同亚型转移灶间的表达差异有限。研究表明，TROP2、VTCN1、NECTIN4、HER2和HER3是具有潜力的靶点，因为它们在肿瘤组织中的mRNA表达高于正常组织。利用探索性免疫组化分析在蛋白水平上证实了这一发现。靶点之间的相关性分析可为双特异性ADC的设计提供参考。综上，本研究结果可为转移性乳腺癌药物设计与优先级确定提供有价值的依据。

### 第二部分 AI 大师评价

该研究基于尸检样本系统性分析了转移性乳腺癌中抗体-药物偶联物靶点的表达谱，填补了靶点表达异质性方面的重要空白。通过RNA测序和免疫组化验证，作者确定了多种在转移灶中高表达且与正常组织差异显著的潜在治疗靶点。研究在方法学上严谨，样本来源具有独特性，结果能为双特异性ADC的设计与临床开发提供参考。其局限性在于样本量相对有限及尸检样本可能存在降解或代表性偏差。

---

## 11. 勘误：RNA结合蛋白RALY通过介导microRNA加工在结直肠癌中重新编程线粒体代谢。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41448882)
**期刊：** Gut
**PMID：** 41448882
**DOI：** 10.1136/gutjnl-2020-320652corr1

### 第一部分 原文与翻译

**英文原标题：** Correction: RNA-binding protein RALY reprogrammes mitochondrial metabolism via mediating miRNA processing in colorectal cancer.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文献为对原始研究的更正，涉及RNA结合蛋白RALY在结直肠癌中调控线粒体代谢和miRNA加工的机制。尽管未提供摘要，但其内容提示研究聚焦于分子层面能量代谢重编程及非编码RNA调控网络。此类研究有助于揭示肿瘤代谢重塑的关键节点，为精准治疗提供潜在靶点。然而作为勘误说明，其新增或修订内容主要在于纠正原文中的数据或表述错误，科研创新性有限。

---

## 12. TL1A激活的T细胞在伴肛周瘘型克罗恩病患者中重塑直肠黏膜

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41448881)
**期刊：** Gut
**PMID：** 41448881
**DOI：** 10.1136/gutjnl-2025-336246

### 第一部分 原文与翻译

**英文原标题：** TL1A-activated T cells remodel the rectal mucosa in patients with Crohn's disease with perianal fistulising disease.

> **英文摘要：**
> BACKGROUND: Perianal fistulising disease (PFD) is a complication that affects about 20% of patients with Crohn's disease (CD) whose aetiology remains unknown.
> 
> OBJECTIVES: To identify predisposing events driving fistula formation.
> 
> DESIGN: Rectal biopsies from patients with CD with or without PFD (CD+PFD and CD, respectively; n=31) were collected and subjected to single-cell RNA sequencing. Functional analyses were conducted using peripheral CD3 T cells, intestinal tissue explants, primary fibroblasts and two-dimensional epithelial monolayer cell cultures.
> 
> RESULTS: The rectal mucosa of patients with CD+PFD is imprinted with cellular and transcriptomic alterations specific to PFD and independent of luminal inflammation, potentially driven by tumour necrosis factor-like ligand 1A (TL1A) activation in CD4 T cells. We identified lymphotoxin beta ( or its functional heterotrimer LTαβ) as a novel mediator downstream of TL1A that, along with interleukin (IL)-22, induces a PFD-associated signature in rectal fibroblast and epithelial cells, respectively. This signature includes an increased abundance of fibroblasts, an induction of matrix-degrading enzymes, transcriptomic rewiring of the lamina propria S1 fibroblasts and an anti-bacterial and immune responses in epithelial cells. Notably, the induction of LTαβ and IL-22 occurs independently of tumour necrosis factor (TNF) signalling, revealing a new TL1A-LTαβ/IL-22 axis that remains active under anti-TNF therapy.
> 
> CONCLUSION: Our findings revealed unique cellular alterations in the rectum of patients with CD+PFD, highlighting the previously unrecognised involvement of TL1A in mediating this signature and supporting the need for exploring the role of TL1A inhibition as a therapeutic approach for PFD.

> **中文摘要：**
> 背景：肛周瘘性疾病（PFD）是克罗恩病（CD）的一种并发症，约影响20%的患者，其病因仍不清楚。
> 
> 研究目的：确定驱动瘘管形成的易感事件。
> 
> 研究设计：收集伴或不伴PFD的CD患者（分别为CD+PFD组与CD组，n=31）的直肠活检标本，进行单细胞RNA测序。功能分析采用外周CD3阳性T细胞、肠组织离体培养、原代成纤维细胞以及二维上皮单层细胞培养体系进行。
> 
> 结果：CD+PFD患者的直肠黏膜呈现独特的细胞学与转录组变化，这些改变特异性地与PFD相关，且独立于腔内炎症，可能由CD4 T细胞中肿瘤坏死因子样配体1A（TL1A）的活化所驱动。我们鉴定出淋巴毒素β（或其功能性异三聚体LTαβ）是位于TL1A下游的新型介质，能与白介素（IL）-22共同在直肠成纤维细胞与上皮细胞中分别诱导出与PFD相关的转录特征。该特征包括成纤维细胞数量增加、基质降解酶的诱导、固有层S1成纤维细胞的转录重编程，以及上皮细胞的抗菌和免疫反应增强。值得注意的是，LTαβ和IL-22的诱导独立于肿瘤坏死因子（TNF）信号通路，提示一种在抗TNF治疗下仍保持活性的新的TL1A–LTαβ/IL-22轴。
> 
> 结论：我们的研究揭示了CD+PFD患者直肠中独特的细胞改变，强调了以往未被认识到的TL1A在该分子特征中的介导作用，并支持进一步探索TL1A抑制作为PFD治疗策略的潜力。

### 第二部分 AI 大师评价

该研究以单细胞转录组学为核心手段，揭示了伴肛周瘘的克罗恩病患者直肠黏膜的特异性分子和细胞变化。通过功能实验，研究者发现TL1A通过下游的LTαβ和IL-22信号共同重塑成纤维细胞与上皮细胞的转录状态，形成独立于TNF的炎症通路。此发现拓展了对瘘管形成分子机制的理解，提示TL1A可能成为治疗PFD的新靶点。研究创新性强，但样本量较小，仍需进一步临床验证。

---

## 13. 通过致病性NETosis的激活加剧实验性结肠炎及结肠炎相关结直肠癌的发生。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41448880)
**期刊：** Gut
**PMID：** 41448880
**DOI：** 10.1136/gutjnl-2025-335887

### 第一部分 原文与翻译

**英文原标题：** exacerbates experimental colitis and colitis-associated colorectal cancer via pathogenic NETosis activation.

> **英文摘要：**
> BACKGROUND: a species enriched in ulcerative colitis (UC) patients, is implicated in chronic inflammation. However, its mechanistic role in UC progression and colitis-associated colorectal cancer (CAC) remains unclear.
> 
> OBJECTIVE: This study investigates the pathogenic role of  in UC and CAC, focusing on its induction of neutrophil extracellular traps (NETs) and underlying mechanisms.
> 
> DESIGN: Clinical stool samples from UC patients and healthy controls were analysed for  abundance. Murine models of dextran sulphate sodium (DSS)-induced colitis and azoxymethane/DSS-induced CAC were used to evaluate bacterial pathogenicity. RNA sequencing and metabolomic analyses were conducted on germ-free mice with monocolonisation, and in vitro cell experiments were carried out to elucidate the role of bacterial metabolites in NETosis.
> 
> RESULTS: was significantly enriched in UC patients and exacerbated colitis and CAC in mice by expanding colonic neutrophils and NETs formation. Metabolomic profiling revealed that  enhances the host's carbohydrate metabolic capacity, leading to increased production of succinic acid (Suc) and 6-hydroxyhexanoic acid (6-HHA). These metabolites activated gasdermin D (GSDMD)-dependent NETosis in lipopolysaccharide-primed neutrophils through the succinate receptor 1/G protein-coupled receptor 84 signalling pathway. Conversely, neutrophil-specific GSDMD deletion attenuated metabolite-driven tumourigenesis.
> 
> CONCLUSION: Our findings identify  as a critical microbial driver of UC and CAC pathogenesis. This bacterium significantly accelerates disease progression by producing specific metabolites (Suc and 6-HHA) that induce pathogenic NETosis. Targeting this bacterium or its metabolic axis offers novel therapeutic strategies for inflammation-driven colorectal carcinogenesis.

> **中文摘要：**
> 背景：一种在溃疡性结肠炎（UC）患者中富集的菌种与慢性炎症相关。然而，其在UC进展及结肠炎相关结直肠癌（CAC）中的机制性作用仍不清楚。
> 
> 目的：本研究旨在探讨该菌在UC和CAC中的致病作用，重点关注其诱导中性粒细胞胞外诱捕网（NETs）形成的机制。
> 
> 设计：分析UC患者及健康对照者的临床粪便样本以检测该菌丰度。采用葡聚糖硫酸钠（DSS）诱导的鼠结肠炎模型及叠氮甲烷/DSS诱导的CAC模型评估其致病性。对无菌小鼠进行单一菌定殖后实施RNA测序与代谢组学分析，并开展体外细胞实验以阐明菌株代谢产物在NETosis中的作用。
> 
> 结果：该菌在UC患者中显著富集，并通过扩大结肠中性粒细胞数量及促进NET形成，加重小鼠的结肠炎及CAC。代谢组学分析显示，该菌增强宿主的碳水化合物代谢能力，导致琥珀酸（Suc）和6-羟基己酸（6-HHA）产量升高。这些代谢物通过琥珀酸受体1/G蛋白偶联受体84信号通路，在脂多糖预处理的中性粒细胞中激活依赖于气体dermin D（GSDMD）的NETosis。相反，中性粒细胞特异性GSDMD缺失可减弱代谢物驱动的肿瘤形成。
> 
> 结论：研究发现该菌是UC及CAC发病机制中的关键微生物驱动因素。该菌通过产生特定代谢产物（Suc和6-HHA）诱导致病性NETosis，从而显著加速疾病进展。靶向该菌或其代谢轴，为炎症驱动的结直肠癌提供了新的治疗策略。

### 第二部分 AI 大师评价

该研究揭示了一种与溃疡性结肠炎患者富集相关的菌株在结肠炎及炎症相关结直肠癌中的促病机制，强调其通过代谢产物诱导中性粒细胞NETosis的关键作用。研究采用临床样本分析、动物模型、代谢组学与分子实验的多层验证，机制阐释较为深入。其创新点在于发现代谢物-Suc/6-HHA–GSDMD–NETosis通路的新型炎症-肿瘤关联机制。然而，由于研究基于动物模型及部分体外结果，对人群转化的可行性仍需进一步验证。

---

## 14. 靶向癌症干细胞可增强代谢功能障碍相关脂肪变性肝病相关肝细胞癌的多激酶抑制剂治疗效果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41448879)
**期刊：** Gut
**PMID：** 41448879
**DOI：** 10.1136/gutjnl-2025-336527

### 第一部分 原文与翻译

**英文原标题：** Targeting cancer stem cells enhances multikinase inhibitor therapy in metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma.

> **英文摘要：**
> OBJECTIVE: Metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma (MASLD-HCC) is an emerging malignancy with limited therapeutic options. The identity and function of cancer stem cells (CSCs) in MASLD-HCC remain poorly understood. In this study, we characterised CSCs in MASLD-HCC and investigated their contribution to MASLD-HCC tumourigenesis and therapy response.
> 
> DESIGN: We performed expression profiling in human MASLD-HCC samples (n=29 pairs of tumour and adjacent normal tissues). Advanced  genetic lineage tracing coupled with single-cell RNA sequencing was used to characterise CD133 CSCs in preclinical models. To establish causality, we developed a hepatocyte-specific CD133-overexpressing mouse model of MASLD-HCC. We identified CD133 protein interactors by mass spectrometry. A novel strategy combining CD133-targeted small interfering RNA (siRNA) nanoparticles with first-line therapy was assessed in clinically relevant MASLD-HCC models.
> 
> RESULTS: CD133 CSCs were significantly enriched in human MASLD-HCC tumours and positively correlated with established markers of malignancy.  genetic lineage tracing in mice revealed that CD133 cells exhibit hallmark CSC properties, including self-renewal, tumour-initiating capacity and multipotent differentiation, as compared with CD133 counterparts. Hepatocyte-specific CD133 overexpression in mice accelerated MASLD-HCC tumourigenesis. Mechanistically, CD133 interacts with myosin heavy chain 9 (MYH9) to stabilise active β-catenin, thereby propagating Wnt/β-catenin signalling that drives CSC phenotypes and tumourigenic potential. Therapeutically, genetic ablation of CD133 cells or systemic delivery of CD133-siRNA nanoparticles potently sensitised MASLD-HCC to sorafenib and lenvatinib, significantly improving outcomes in MASLD-HCC.
> 
> CONCLUSION: This study established CD133 CSCs as critical mediators through the CD133-MYH9/β-catenin axis in MASLD-HCC. Targeting CD133 enhances multikinase inhibitor efficacy, offering a promising therapeutic strategy for MASLD-HCC.

> **中文摘要：**
> 研究目的：代谢功能障碍相关脂肪变性肝病相关肝细胞癌（MASLD-HCC）是一种新兴的恶性肿瘤，治疗手段有限。MASLD-HCC 中癌症干细胞（CSC）的身份与功能仍不清楚。本研究旨在表征 MASLD-HCC 中的 CSC，并探讨其在肿瘤发生及治疗反应中的作用。
> 
> 研究设计：我们对人类 MASLD-HCC 标本（共29对肿瘤与邻近正常组织）进行了表达谱分析。在临床前模型中，采用先进的遗传谱系追踪结合单细胞 RNA 测序的方法，表征 CD133 癌症干细胞。为确立因果关系，构建了肝细胞特异性 CD133 过表达的 MASLD-HCC 小鼠模型。利用质谱鉴定了 CD133 蛋白相互作用分子。将 CD133 靶向小干扰 RNA（siRNA）纳米颗粒与一线治疗药物联合应用，并在临床相关 MASLD-HCC 模型中评价其疗效。
> 
> 研究结果：人 MASLD-HCC 中的 CD133 癌症干细胞显著富集，并与已知恶性标志物呈正相关。小鼠遗传谱系追踪显示，CD133 阳性细胞相较于阴性细胞具有典型的癌症干细胞特征，包括自我更新、肿瘤起始能力及多向分化潜能。肝细胞特异性 CD133 过表达的小鼠中，MASLD-HCC 的肿瘤发生显著加速。在机制上，CD133 与肌球蛋白重链9（MYH9）相互作用，稳定活化的 β-连环蛋白（β-catenin），从而促进驱动 CSC 表型及致瘤潜能的 Wnt/β-catenin 信号通路。治疗方面，CD133 细胞的基因敲除或系统递送 CD133-siRNA 纳米颗粒可显著增强 MASLD-HCC 对索拉非尼和仑伐替尼的敏感性，改善治疗结局。
> 
> 研究结论：本研究确立了 CD133 癌症干细胞通过 CD133-MYH9/β-catenin 轴在 MASLD-HCC 中发挥关键介导作用。靶向 CD133 可提高多激酶抑制剂疗效，为 MASLD-HCC 提供了一种具有前景的治疗策略。

### 第二部分 AI 大师评价

本研究聚焦代谢功能障碍相关脂肪变性肝病型肝癌中癌症干细胞的生物学作用及治疗靶向价值。通过人类样本分析、谱系追踪、单细胞测序及小鼠模型，系统揭示了 CD133-MYH9/β-catenin 信号通路在维持肿瘤干性和促进肿瘤生成中的机制。进一步证实靶向 CD133 可增强索拉非尼与仑伐替尼多激酶抑制剂的疗效，显示了转化潜能。研究的创新性在于提出了 CSC 靶向与多激酶治疗联合的新模式，但仍需更多临床验证以评估安全性与长期疗效。

---

## 15. 移植日内时间对同种异体造血干细胞移植结局的影响：一项验证性队列研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41448834)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41448834
**DOI：** 10.1136/jitc-2025-013372

### 第一部分 原文与翻译

**英文原标题：** Influence of time-of-day of graft infusion on allogeneic hematopoietic stem cell transplantation outcomes: a validation cohort study.

> **英文摘要：**
> The biological clock plays a central role in hematopoiesis and immune regulation, making circadian rhythms an increasingly important factor in immunotherapies and cellular therapies such as allogeneic hematopoietic stem cell transplantation (allo-HSCT). Previous work by Hou  suggested that afternoon graft infusions were associated with a higher risk of acute graft-versus-host disease and worse survival, highlighting a potential role for infusion timing in shaping transplant outcomes.To further investigate this, we performed a retrospective analysis of 368 patients who underwent allo-HSCT at Geneva University Hospitals between 2015 and 2024. Observing that infusion timing patterns at our center differed from those reported by Hou , we applied a data-driven approach using receiver operating characteristic analysis, which identified 11:17 as the optimal cut-off for overall survival.Stratification using this threshold revealed that patients receiving grafts before 11:00 had significantly improved 2-year overall survival and lower non-relapse mortality compared with those infused later in the day, with no differences in relapse or engraftment rates.These findings suggest that infusion timing may be an important, under-recognized factor influencing allo-HSCT outcomes. Prospective clinical trials are needed to confirm these observations and explore their applicability across different clinical contexts.

> **中文摘要：**
> 生物钟在造血和免疫调节中发挥核心作用，这使得昼夜节律在免疫治疗和细胞治疗（如同种异体造血干细胞移植，allo-HSCT）中成为日益重要的因素。此前 Hou 的研究表明，下午进行的移植物输注与更高的急性移植物抗宿主病风险及较差的生存率相关，提示输注时间可能在塑造移植结局中具有潜在作用。为进一步探讨这一现象，我们对2015年至2024年间在日内瓦大学医院接受 allo-HSCT 的368例患者进行了回顾性分析。我们发现本中心的输注时间模式与 Hou 报道的不同，因此采用基于数据的方法并使用受试者工作特征（ROC）分析，确定11:17为预测总体生存率的最佳截断点。基于该阈值的分层分析显示，与在当天较晚时间接受移植物的患者相比，于11:00前接受移植的患者具有显著改善的两年总体生存率和更低的非复发性死亡率，而复发率与植入率不存在差异。这些结果提示，输注时间可能是一个重要但尚未广泛认识的影响 allo-HSCT 结局的因素。需要前瞻性临床试验来验证这些观察结果，并探讨其在不同临床情境中的适用性。

### 第二部分 AI 大师评价

本研究关注同种异体造血干细胞移植中“移植日内时间”对结局的潜在影响，基于368例患者的回顾性分析提出上午输注可能具有生存优势。研究采用ROC分析确定优化阈值，并验证了输注时间与总体生存及非复发死亡的关联。其创新点在于将昼夜节律生物学引入移植时序的研究框架，提出了可操作的临床变量作为干预点。局限性在于研究为单中心回顾性研究，仍需前瞻性、多中心验证来支持因果结论。

---

## 16. NX-1607：解除Cbl-b制动，通过MAPK/ERK通路促进T细胞活化

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41448833)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41448833
**DOI：** 10.1136/jitc-2025-012979

### 第一部分 原文与翻译

**英文原标题：** NX-1607: lifting the Cbl-b brake to promote T cell activation through MAPK/ERK pathways.

> **英文摘要：**
> Casitas B lymphoma-b (Cbl-b) is an E3 ubiquitin ligase that serves as a critical brake on immune cell activations. It negatively fine-tunes immune responses through ubiquitination of signaling proteins. Cbl-b deficiency in mice leads to spontaneous tumor rejection and induces only mild, non-lethal autoimmunity, highlighting its potential as a promising immunotherapy target. NX-1607 is the first oral small molecule inhibitor of Cbl-b and it is currently in phase I clinical trial. A recent publication employed high-throughput drug combination screening to systematically elucidate the molecular pathways by which NX-1607 enhances T cell activation. The authors administered 81 well-characterized inhibitors to Jurkat T cells under CD3-stimulated and unstimulated conditions in the presence of NX-1607. Inhibitors of the MAPK/ERK pathway significantly attenuated NX-1607-enhanced T cell activation as indicated by CD69 markers. Proto-oncogene tyrosine-protein kinase Src (SRC) family kinase inhibitors also reduced both CD69 activation markers and the phosphorylation of PLCγ1 and HCLS1 which are upstream of MAPK/ERK pathways. These findings were validated in an immunocompetent B-cell lymphoma mouse model, where NX-1607 consistently upregulated PLCγ1 and ERK phosphorylation. Together, this work delineates a PLCγ1-MAPK/ERK axis through which Cbl-b inhibition unleashes T cell activation, providing critical insight for the development of NX-1607 based immunotherapy.

> **中文摘要：**
> Casitas B淋巴瘤-b（Cbl-b）是一种E3泛素连接酶，在免疫细胞活化中起关键的抑制作用。它通过对信号蛋白的泛素化修饰来负向调节免疫反应。小鼠中缺失Cbl-b可导致自发性肿瘤清除，并仅引发轻度、非致死性的自身免疫现象，这突显了其作为免疫治疗靶点的潜力。NX-1607是首个可口服的Cbl-b小分子抑制剂，目前正处于I期临床试验阶段。近期一项研究采用高通量药物组合筛选，系统阐明了NX-1607增强T细胞活化的分子通路。研究者向在CD3刺激和非刺激条件下的Jurkat T细胞中加入NX-1607，并联合81种已充分表征的抑制剂。结果显示，MAPK/ERK通路的抑制剂显著减弱了NX-1607增强的T细胞活化效应（以CD69标志物为指标）。原癌基因酪氨酸蛋白激酶Src（SRC）家族抑制剂同样减少了CD69激活标志物的表达，并降低了MAPK/ERK通路上游分子PLCγ1和HCLS1的磷酸化水平。这些发现通过免疫健全的B细胞淋巴瘤小鼠模型得到了验证，其中NX-1607持续上调了PLCγ1和ERK的磷酸化。总体而言，该研究描绘了Cbl-b抑制解除后通过PLCγ1-MAPK/ERK轴促进T细胞活化的机制，为NX-1607相关免疫治疗的开发提供了关键见解。

### 第二部分 AI 大师评价

本研究以Cbl-b为免疫抑制靶点，探讨其小分子抑制剂NX-1607在促进T细胞活化中的作用机制。作者通过高通量联合药物筛选和多模型验证，揭示了NX-1607主要通过激活PLCγ1-MAPK/ERK信号轴来增强T细胞反应。该研究不仅阐明了Cbl-b抑制的关键分子通路，也为口服免疫调节剂的开发提供了实验依据。其创新性在于系统性整合信号通路分析与体内验证，但未来仍需进一步评估其长期安全性与临床疗效。

---

## 17. 非α偏向型IL-2增强肿瘤内及皮下注射CpG/α-OX40疗法，在小鼠中激活系统性抗肿瘤免疫。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41448832)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41448832
**DOI：** 10.1136/jitc-2025-012336

### 第一部分 原文与翻译

**英文原标题：** Non-α-biased IL-2 enhances both intratumoral and subcutaneous CpG/α-OX40 therapy, unleashing systemic antitumor immunity in mice.

> **英文摘要：**
> BACKGROUND: The CpG/α-OX40 in situ vaccine strategy has shown efficacy in immune-hot tumors but remains ineffective in immune-cold tumors possibly due to immunosuppressive microenvironments characterized by myeloid-derived suppressor cells (MDSCs) infiltration and T cell exclusion. This study aims to investigate the antitumor effect of non-α-biased IL-2 combined with CpG/α-OX40 in mice.
> 
> METHODS: Using 4T1 breast cancer and CT26 colon cancer models, we evaluated the antitumor effects of combining CpG/α-OX40 with a non-α-biased IL-2 variant via both intratumoral and subcutaneous routes. Tumor growth, lung metastasis, immune profile, and  function analysis were assessed through flow cytometry, transcriptomic analysis, and T cell suppression assays.
> 
> RESULTS: The combination therapy significantly inhibited primary and distant tumor growth and reduced lung metastasis in 4T1 models. Subcutaneous administration induced complete tumor regression in 55% (5/9) of CT26-tumor-bearing mice and conferred durable tumor-specific memory. Mechanistically, the treatment enhanced CD8 T cell activation, metabolic reprogramming, and IFN-γ production, while suppressing MDSC expansion and immunosuppressive function.
> 
> CONCLUSIONS: These findings demonstrate that non-α-biased IL-2 synergizes with CpG/α-OX40 to overcome microenvironmental immunosuppression and achieve systemic antitumor immunity via a subcutaneous route, offering a translatable combinatorial strategy for immune-cold tumors.

> **中文摘要：**
> 背景：CpG/α-OX40原位疫苗策略已在免疫“热”型肿瘤中显示出疗效，但在免疫“冷”型肿瘤中仍无效，这可能是由于髓源性抑制性细胞（MDSCs）浸润和T细胞排斥所特征的免疫抑制性微环境所致。本研究旨在探讨非α偏向型IL-2与CpG/α-OX40联合使用在小鼠中的抗肿瘤作用。
> 
> 方法：采用4T1乳腺癌和CT26结肠癌模型，通过肿瘤内或皮下注射途径，评估CpG/α-OX40与非α偏向型IL-2变体联合的抗肿瘤效果。通过流式细胞术、转录组分析及T细胞抑制实验评估肿瘤生长、肺转移、免疫特征及功能变化。
> 
> 结果：联合治疗在4T1模型中显著抑制了原发及远处肿瘤生长，并减少了肺转移。皮下注射方式在55%（5/9）的CT26肿瘤负荷小鼠中诱导了完全肿瘤消退，并产生了持久的肿瘤特异性免疫记忆。机制上，该治疗增强了CD8 T细胞活化、代谢重编程及IFN-γ产生，同时抑制了MDSC的扩增及免疫抑制功能。
> 
> 结论：这些发现表明，非α偏向型IL-2可与CpG/α-OX40协同，通过皮下注射途径克服肿瘤微环境免疫抑制，从而诱导系统性抗肿瘤免疫，为免疫“冷”型肿瘤提供了一种可转化的联合治疗策略。

### 第二部分 AI 大师评价

该研究旨在通过非α偏向型IL-2与CpG/α-OX40联合疗法增强抗肿瘤免疫反应。研究采用乳腺癌和结肠癌小鼠模型，比较肿瘤内与皮下注射给药效果。结果显示，联合治疗不仅抑制了原发及远处肿瘤，还促进了长期免疫记忆形成。机制分析揭示该疗法能够激活CD8 T细胞、调节代谢并抑制MDSC免疫抑制。本研究创新地提出了皮下注射联合免疫疗法的可转化潜力，为应对免疫“冷”型肿瘤提供了新策略，然而尚需进一步验证其临床安全性与广泛适用性。

---

## 18. AstroID资源：用于纵向生物标志物发现的可扩展关系型数据库结构

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41448831)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41448831
**DOI：** 10.1136/jitc-2025-012235

### 第一部分 原文与翻译

**英文原标题：** AstroID resource: a scalable, relational database structure for longitudinal biomarker discovery.

> **英文摘要：**
> BACKGROUND: The biological sciences are producing increasingly larger datasets for biomarker discovery. While common data models have been developed for medical terms as they relate to patient health outcomes, a data model that supports longitudinal tracking of biospecimens and relating them against an individual patient experience is a large, unmet need.
> 
> METHOD: A structure and associated taxonomy were achieved through a six-tier build in Research Electronic Data CAPture (REDCap), which organizes the complexity of the therapeutic decisions, biospecimens, and outcomes that characterize a longitudinal patient experience. Modules were developed to support export of REDCap data into a Structured Query Language (SQL) format for merging with extended biomarker data, also housed in SQL.
> 
> RESULTS: The resultant AstroID resource is a relational structure for clinical and biospecimen data that meets several desired goals: searchable, flexible, generic, Health Insurance Portability and Accountability Act-compliant, auditable, and easy-to-use. The essential elements forming the core of the six-tiered build are provided, so others can readily adopt this schema, as well as an example of an extended, customized build to support biomarker discovery for patients with melanoma. Two examples where this data structure was used to support biomarker discovery and development are described, and example queries of the database are also presented. To the extent possible, the data dictionary was aligned with large data models, such as those for the National Institutes of Health's Human Tumor Atlas Network. The structure can readily scale to accommodate thousands of patients, multimodality data, and spatial characterization of billions of cells. Radiologic imagery can also be included along with pathology imagery to support spatial studies, including artificial intelligence-driven analyses.
> 
> CONCLUSIONS: This effort provides a database model for investigators conducting research on large volumes of biospecimens with clinical annotation. We have now deployed this structure in our laboratories and have over 1B cells spatially mapped, each effectively tagged with the clinical information from longitudinal patient experiences. While the description uses the example of cancer biomarkers, this data structure could be used to characterize longitudinal biospecimens from any disease process. In the near future, automatic synchronization between the electronic medical record and one or more AstroID databases is anticipated.

> **中文摘要：**
> 背景：生物科学在生物标志物发现方面正在产出越来越庞大的数据集。虽然已经开发了用于将医学术语与患者健康结局关联的通用数据模型，但能够支持生物样本的纵向追踪并将其与个体患者经历关联的数据模型仍是一个巨大的未满足需求。
> 
> 方法：本研究通过在研究性电子数据采集系统（Research Electronic Data CAPture，REDCap）中构建六层结构及其相关分类体系，实现了对治疗决策、生物样本和结果等纵向患者经历中复杂信息的系统化组织。开发了模块以支持REDCap数据导出为结构化查询语言（SQL）格式，从而可与同样存储于SQL的扩展生物标志物数据进行整合。
> 
> 结果：由此产生的AstroID资源是一种临床与生物样本数据的关系型结构，满足多项理想目标：可检索、灵活、通用、符合《健康保险携带与责任法案》（HIPAA）规范、可审计且易于使用。文中提供了构成六层结构核心的基本要素，方便他人直接采用该模式，并展示了一个为黑色素瘤患者的生物标志物发现而定制的扩展示例。文中描述了两例利用该数据结构支持生物标志物发现与开发的实例，并提供了数据库查询示例。数据字典在可能范围内与大型数据模型（如美国国立卫生研究院的人类肿瘤图谱网络）保持一致。该结构可轻松扩展，以容纳数千名患者、多模态数据以及数十亿细胞的空间表征。此外，还可将影像学资料与病理图像一并纳入，以支持包括人工智能驱动分析在内的空间研究。
> 
> 结论：本研究为从事带有临床注释的大规模生物样本研究的科学家提供了一种数据库模型。目前该结构已在实验室中部署，实现了超过十亿个细胞的空间映射，每个细胞均与纵向患者经历的临床信息有效关联。尽管示例以癌症生物标志物为主，但这种数据结构也适用于任何疾病过程的纵向生物样本特征表征。预计在不久的将来，将实现电子病历与一个或多个AstroID数据库之间的自动同步。

### 第二部分 AI 大师评价

该研究旨在解决生物样本纵向研究中的数据组织与追踪难题，提出了一种可扩展的关系型数据库模型AstroID。作者基于REDCap框架设计了六层结构，并实现了与SQL数据库的整合，以支持多模态和高维生物标志物分析。结果显示AstroID具有高度可扩展性、灵活性与可审计性，能够存储数十亿细胞的空间数据并支持AI驱动的影像分析。该工作在大型生物数据标准化与临床信息整合领域具有创新性，但其广泛应用仍需更多跨疾病验证与临床系统集成测试。

---

## 19. 他利莫金拉赫帕瑞普韦克用于晚期黑色素瘤挽救治疗的真实世界疗效研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41448830)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41448830
**DOI：** 10.1136/jitc-2025-013564

### 第一部分 原文与翻译

**英文原标题：** Real-world outcomes of talimogene laherparepvec as salvage therapy for advanced melanoma.

> **英文摘要：**
> BACKGROUND: Talimogene laherparepvec (T-VEC) is an oncolytic herpes simplex virus therapy approved for treatment of unresectable and metastatic melanoma. However, real-world use often occurs in heavily pretreated patients, where evidence of effectiveness remains limited. This study evaluates treatment responses and clinical factors influencing T-VEC outcomes in patients with diverse treatment histories.
> 
> METHODS: We analyzed patients with metastatic melanoma treated with T-VEC between 2015 and 2024. Objective responses (OR), complete response (CR) and partial response were assessed using univariate and multivariate Cox regression models. Durability of responses, progression-free survival (PFS), and overall survival (OS) were evaluated using Kaplan-Meier estimates.
> 
> RESULTS: Among 121 patients, 105 (87%) patients received ≥1 prior lines of systemic therapy; 48 (40%) had a current or prior history of distant metastatic disease, and 42 (35%) had both injectable and non-injectable disease at the T-VEC initiation. Median PFS was 12.2 months (95% CI 6.2 to 20.9), and median OS was 35.5 months (95% CI 25.8 to 63.9). Of 113 evaluable patients, 76 (67%, 95% CI 58% to 76%) achieved an OR, including 39 (35%, 95% CI 26% to 44%) CR. The probability OR by 6 months was 56% (95% CI 46% to 65%). Of the 39 patients achieving CR, 37 (95%) remained alive and progression-free at last follow-up (median 19.1 months). In multivariate analysis, the adjusted HR (aHR) for OR in patients with non-injectable distant metastases at T-VEC initiation relative to those without was 0.43 (95% CI 0.23 to 0.78; p=0.006). The aHR for OR among those immunosuppressed compared with those not immunosuppressed was 0.18 (95% CI 0.04 to 0.69; p=0.013), indicating a reduced likelihood of response for patients who were immunosuppressed. Unadjusted HRs for achieving an OR after 1, 2, and ≥3 prior therapies (vs none) were 1.20 (95% CI 0.57 to 2.52; p=0.627), 1.21 (95% CI 0.52 to 2.80; p=0.653), and 0.77 (95% CI 0.35 to 1.68; p=0.507), respectively.
> 
> CONCLUSIONS: This study demonstrates T-VEC's potential efficacy in achieving meaningful disease control and response durability in patients with unresectable and/or metastatic melanoma, including those with diverse prior-treatment histories and comorbidities.

> **中文摘要：**
> 背景：他利莫金拉赫帕瑞普韦克（T-VEC）是一种用于治疗不可切除及转移性黑色素瘤的溶瘤单纯疱疹病毒疗法。然而，在真实世界中，T-VEC 的使用往往见于经多种治疗预处理的患者，其有效性证据仍较为有限。本研究旨在评估不同治疗史患者接受 T-VEC 治疗的反应情况及影响疗效的临床因素。
> 
> 方法：本研究分析了2015年至2024年期间接受 T-VEC 治疗的转移性黑色素瘤患者。通过单变量及多变量 Cox 回归模型评估客观缓解（OR）、完全缓解（CR）及部分缓解。采用 Kaplan-Meier 法估算缓解持续时间、无进展生存期（PFS）及总生存期（OS）。
> 
> 结果：在121例患者中，105例（87%）曾接受至少一种系统治疗；48例（40%）有当前或既往远处转移病史，42例（35%）在启动 T-VEC 时同时存在可注射和不可注射病灶。中位 PFS 为12.2个月（95% CI 6.2–20.9），中位 OS 为35.5个月（95% CI 25.8–63.9）。在113例可评估患者中，76例（67%，95% CI 58%–76%）获得客观缓解，其中39例（35%，95% CI 26%–44%）达到完全缓解。6个月时客观缓解概率为56%（95% CI 46%–65%）。在39例达到完全缓解的患者中，37例（95%）在最后随访（中位19.1个月）时仍存活且无进展。在多变量分析中，治疗开始时存在不可注射远处转移的患者相比无者，其客观缓解调整后风险比（aHR）为0.43（95% CI 0.23–0.78；p=0.006）。免疫抑制患者与非免疫抑制者相比，其 OR 的 aHR 为0.18（95% CI 0.04–0.69；p=0.013），提示免疫抑制状态降低应答可能性。未调整的 HR 显示，相较于未接受系统治疗的患者，既往接受1、2及≥3线治疗者获得OR的 HR分别为1.20（95% CI 0.57–2.52；p=0.627）、1.21（95% CI 0.52–2.80；p=0.653）及0.77（95% CI 0.35–1.68；p=0.507）。
> 
> 结论：本研究表明，T-VEC 在不可切除及/或转移性黑色素瘤患者中可实现有临床意义的疾病控制及持久缓解效应，即使在既往治疗多样且合并疾病的患者中亦具潜在疗效。

### 第二部分 AI 大师评价

该研究基于真实世界数据，系统评估了T-VEC在多种治疗史的晚期黑色素瘤患者中的疗效与影响因素，具有较强的临床实践关联性。研究采用Cox回归与Kaplan-Meier分析，揭示了免疫抑制状态及远处转移特征对疗效的不利影响。结果显示T-VEC可带来较高的缓解率与持久病情控制，为治疗重度预处理患者提供了有力证据。然而，研究受限于回顾性设计及潜在选择偏倚，仍需前瞻性研究进一步验证。

---

速递结束，祝您工作愉快！